
Claims

1. Use of compound of Formula (Ia) or a pharmaceutically acceptable salt, or solvate thereof in the manufacture of a medicament for the treatment of acute myeloid leukemia:



(Ia)


wherein

A is independently C or N, and at least one A is N;


Het is optionally substituted 6-membered saturated N-heterocyclyl; and

R_1 is halo substituted alkyl, hydroxy, optionally substituted alkyoxy, optionally substituted acyloxy, or optionally substituted aminoacyloxy.

2. The use according to claim 1, wherein compound of Formula (Ia) is represented by Formula (Ia') or (Ia"):



(Ia')





(Ia").

3. The use according to claims 1 or 2, wherein Het is selected from optionally substituted piperidinyl, optionally substituted piperazinyl, and optionally substituted morpholinyl.

4. The use according to any one of claims 1 to 3, wherein the optional substituent on Het is selected from halo, cyano, oxo, and C_1-C_6 alkyl.


5. The use according to any one of claims 1 to 4, wherein R_1 is selected from -OH,








wherein ~ denotes a bond to the Markush structure at R_1; and
alkyl is C_1-C_6 alkyl.


6. The use according to any one of claims 1 to 5, wherein the compound of Formula (Ia) is selected from







































































.

7. The use according to any one of claims 1 to 6, wherein the compound of Formula (Ia) is selected from

8. A compound of Formula (Ia) or a pharmaceutically acceptable salt, or solvate thereof for use in therapy:



(Ia)


wherein

A is independently C or N, and at least one A is N;

Het is optionally substituted 6-membered heterocycyl; and

R_1 is halo substituted alkyl, hydroxy, optionally substituted alkyoxy, optionally substituted acyloxy, or optionally substituted aminoacyloxy.

9. A compound of Formula (IIa) or a salt, or solvate thereof:



(IIa)

wherein


A is independently C or N;

at least one A is N;


R_1 is halo substituted alkyl, hydroxy, optionally substituted alkyoxy, optionally substituted acyloxy, or optionally substituted aminoacyloxy;

R_3 is H, optionally substituted alkyl or optionally substituted acyl.

10. The compound according to claim 9, wherein compound of Formula (IIa) is represented by Formula (IIa') or (IIa"):




(IIa')



(IIa").


11. The compound according to claim 9 or 10, wherein R_1 is selected from -OH,





wherein ~ denotes a bond to the Markush structure at R_1; and
alkyl is C_1-C_6 alkyl.


12. The compound according to any one of claims 9 to 11, wherein R_3 is H or C_1-C_6 alkyl.


13. The compound according to any one of claims 9 to 12, wherein the compound of Formula (IIa) is selected from






























































.

14. A pharmaceutical composition comprising a compound of Formula (Ia) or (IIa) according to any one of claims 1 to 13, or a pharmaceutically acceptable salt, or solvate thereof.